Petri 2002.

Methods	double blind RCT 7‐9 months
Participants	Total: 191 Sex: female Ethnicity: 55‐57% Caucasian; 25‐27% African‐American Median age: 30‐41yr Inclusion criteria: >10mg prednisolone for 12mths Exclusion criteria: other immunosuppressants
Interventions	Grp 1: DHEA 100mg/dy Grp 2: DHEA 200mg/dy Grp 3: placebo
Outcomes	Stated primary: 'Responder' days of prednisolone <7.5mg SLEDAI (not reported), HRQoL (not reported), Fatigue, (not reported), SLICC (not reported) biological markers
Notes	Funding: Genelabs Technologies Inc
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear